HilleVax Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress
Rhea-AI Summary
HilleVax (HLVX) reported its Q3 2024 financial results, showing cash and equivalents of $189.3 million as of September 30, 2024, down from $303.5 million at year-end 2023. R&D expenses decreased to $20.2 million from $27.3 million in Q3 2023, mainly due to lower clinical development costs. G&A expenses slightly decreased to $6.2 million from $6.6 million. Other income declined to $0.6 million from $2.1 million, primarily due to interest expenses from term loan facility repayment. Net loss improved to $25.8 million compared to $31.8 million in Q3 2023.
Positive
- Net loss improved by $6 million year-over-year to $25.8 million
- R&D expenses reduced by $7.1 million compared to Q3 2023
- G&A expenses decreased by $0.4 million year-over-year
Negative
- Cash position declined by $114.2 million since December 2023
- Other income decreased by $1.5 million due to loan repayment expenses
- Significant ongoing quarterly losses of $25.8 million
Insights
The Q3 results reveal a concerning cash burn rate, with cash reserves declining by
The reduction in G&A expenses and professional service costs, combined with the term loan repayment impacting other income, suggests a focus on cost management. However, without clear revenue streams and ongoing cash burn, the company's runway and ability to fund future development initiatives may be The strategic review and business development activities hint at possible M&A or partnership opportunities being considered.
The company is exploring the potential for continued development of its norovirus vaccine candidates in adults as well as business development related activities and other strategic alternatives
BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended September 30, 2024.
Third Quarter 2024 Financial Results
As of September 30, 2024 and December 31, 2023, the company had cash, cash equivalents and marketable securities totaling
Research and development expenses for the third quarter 2024 were
General and administrative expenses for the third quarter 2024 were
Other income for the third quarter 2024 was
Net loss for the third quarter 2024 was
About HilleVax
HilleVax is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. Its initial programs, HIL-214 and HIL-216, are virus-like particle (VLP) based vaccine candidates in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Globally, norovirus is estimated to result in over approximately 700 million cases of AGE and 200,000 deaths per year, resulting in over
Forward-Looking Statements
The Company cautions you that statements contained in this report regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on the Company’s current beliefs and expectations and include, but are not limited to: the timing and scope of any workforce reductions, the amount and timing of the related charges and costs, and intended objectives and benefits of a workforce reduction; and the Company’s plan to explore the potential for continued development of its norovirus vaccine candidates as well as business development-related activities for these vaccine candidates. Actual results may differ from those set forth in this report due to the risks and uncertainties inherent in the Company’s business, including, without limitation: the preliminary nature of the Company’s estimates of the charges and cash expenditures to be incurred in connection with the recent workforce reduction; the Company may not realize the benefits expected from the workforce reduction, including the Company’s ability to conserve cash; the Company’s ability to retain key personnel; to date the Company has depended primarily on the success of HIL-214, and the Company may be unable to identify a viable development path forward for its vaccine candidates; the Company may be unable to secure partnerships or other strategic collaborations on acceptable terms or at all; and other risks described in the Company’s filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in the Company’s annual report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contact:
Shane Maltbie
IR@hillevax.com
+1-617-213-5054
| HilleVax, Inc. Condensed Consolidated Statement of Operations Data (in thousands, except share and per share data) (unaudited) | ||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | $ | 20,165 | $ | 27,308 | $ | 72,744 | $ | 73,425 | ||||||||
| In-process research and development | — | — | 15,325 | — | ||||||||||||
| General and administrative | 6,215 | 6,603 | 22,836 | 19,629 | ||||||||||||
| Impairment charges | — | — | 8,235 | — | ||||||||||||
| Total operating expenses | 26,380 | 33,911 | 119,140 | 93,054 | ||||||||||||
| Loss from operations | (26,380 | ) | (33,911 | ) | (119,140 | ) | (93,054 | ) | ||||||||
| Total other income | 557 | 2,096 | 5,820 | 6,448 | ||||||||||||
| Net loss | $ | (25,823 | ) | $ | (31,815 | ) | $ | (113,320 | ) | $ | (86,606 | ) | ||||
| Net loss per share, basic and diluted | $ | (0.52 | ) | $ | (0.81 | ) | $ | (2.31 | ) | $ | (2.26 | ) | ||||
| Weighted-average shares of common stock outstanding, basic and diluted | 49,382,277 | 39,039,553 | 49,008,614 | 38,252,981 | ||||||||||||
| HilleVax, Inc. Condensed Consolidated Balance Sheet Data (in thousands) (unaudited) | ||||||||
| September 30, 2024 | December 31, 2023 | |||||||
| Cash, cash equivalents and marketable securities | $ | 189,310 | $ | 303,483 | ||||
| Total assets | 220,622 | 344,434 | ||||||
| Total liabilities | 36,349 | 78,909 | ||||||
| Total stockholders’ equity | 184,273 | 265,525 | ||||||
| Total liabilities and stockholders’ equity | 220,622 | 344,434 | ||||||
FAQ
What was HilleVax (HLVX) net loss in Q3 2024?
How much cash does HilleVax (HLVX) have as of September 30, 2024?
How much did HilleVax (HLVX) spend on R&D in Q3 2024?
